MX374304B - Formulaciones de buprenorfina de liberación sostenida. - Google Patents
Formulaciones de buprenorfina de liberación sostenida.Info
- Publication number
- MX374304B MX374304B MX2019002675A MX2019002675A MX374304B MX 374304 B MX374304 B MX 374304B MX 2019002675 A MX2019002675 A MX 2019002675A MX 2019002675 A MX2019002675 A MX 2019002675A MX 374304 B MX374304 B MX 374304B
- Authority
- MX
- Mexico
- Prior art keywords
- butanol
- chain
- pharmaceutical composition
- organic solvent
- injectable pharmaceutical
- Prior art date
Links
- 229960001736 buprenorphine Drugs 0.000 title abstract 2
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 238000013268 sustained release Methods 0.000 title 1
- 239000012730 sustained-release form Substances 0.000 title 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 abstract 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 abstract 3
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 abstract 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 abstract 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 abstract 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 abstract 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical group CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 abstract 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 abstract 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 abstract 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 abstract 2
- 239000003960 organic solvent Substances 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 abstract 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 229960002903 benzyl benzoate Drugs 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 235000011187 glycerol Nutrition 0.000 abstract 1
- -1 ispropanol Natural products 0.000 abstract 1
- 230000002045 lasting effect Effects 0.000 abstract 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662394168P | 2016-09-13 | 2016-09-13 | |
| PCT/CN2017/101327 WO2018050043A1 (en) | 2016-09-13 | 2017-09-12 | Sustained-release buprenorphine formulations background of invention |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2019002675A MX2019002675A (es) | 2019-08-01 |
| MX374304B true MX374304B (es) | 2025-03-06 |
Family
ID=61619029
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019002675A MX374304B (es) | 2016-09-13 | 2017-09-12 | Formulaciones de buprenorfina de liberación sostenida. |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US10744132B2 (enExample) |
| EP (1) | EP3512518B1 (enExample) |
| JP (1) | JP6929367B2 (enExample) |
| KR (1) | KR102244500B1 (enExample) |
| CN (1) | CN109789137B (enExample) |
| AR (1) | AR110468A1 (enExample) |
| AU (1) | AU2017325910B2 (enExample) |
| BR (1) | BR112019004923A2 (enExample) |
| CA (1) | CA3033046C (enExample) |
| CL (1) | CL2019000624A1 (enExample) |
| CO (1) | CO2019003632A2 (enExample) |
| DK (1) | DK3512518T3 (enExample) |
| ES (1) | ES2934721T3 (enExample) |
| FI (1) | FI3512518T3 (enExample) |
| HR (1) | HRP20230062T8 (enExample) |
| HU (1) | HUE060906T2 (enExample) |
| LT (1) | LT3512518T (enExample) |
| MX (1) | MX374304B (enExample) |
| MY (1) | MY196269A (enExample) |
| PE (1) | PE20190707A1 (enExample) |
| PH (1) | PH12019500466A1 (enExample) |
| PL (1) | PL3512518T3 (enExample) |
| PT (1) | PT3512518T (enExample) |
| RS (1) | RS63894B1 (enExample) |
| RU (1) | RU2747306C2 (enExample) |
| SG (1) | SG11201901294QA (enExample) |
| SI (1) | SI3512518T1 (enExample) |
| SM (1) | SMT202300006T1 (enExample) |
| TW (1) | TWI743193B (enExample) |
| WO (1) | WO2018050043A1 (enExample) |
| ZA (1) | ZA201900890B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1057075C (zh) * | 1997-09-10 | 2000-10-04 | 中国石油化工总公司 | 低碳烯烃直接水合连续生产低碳醇的方法 |
| TWI838372B (zh) | 2018-05-11 | 2024-04-11 | 昱展新藥生技股份有限公司 | 丁基原啡因衍生物之長效注射劑型及結晶型 |
| TWI827777B (zh) * | 2018-12-27 | 2024-01-01 | 昱展新藥生技股份有限公司 | 納曲酮注射型緩釋製劑 |
| EP3936112A1 (en) * | 2020-07-07 | 2022-01-12 | Occlugel | Hydrophilic degradable microspheres for delivering buprenorphine |
| AU2022270208A1 (en) * | 2021-05-05 | 2023-12-07 | Lyndra Therapeutics, Inc. | Gastric residence systems comprising methadone |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2382577C (en) | 1999-08-27 | 2008-01-22 | Southern Research Institute | Injectable buprenorphine microparticle compositions and their use |
| EP1554290B1 (en) | 2002-10-25 | 2009-09-30 | Euro-Celtique S.A. | Analogs and prodrugs of buprenorphine |
| CN1263760C (zh) * | 2002-11-12 | 2006-07-12 | 财团法人奇美医院 | 新颖的丁丙诺啡酯衍生物及其制备方法，以及长效作用镇痛药学组合物 |
| TWI226830B (en) * | 2002-11-12 | 2005-01-21 | Chi Mei Foundation Medical Ct | Novel ester derivatives of buprenorphine and their preparation processes, and long acting analgesic pharmaceutical compositions |
| ATE382050T1 (de) * | 2002-11-25 | 2008-01-15 | Chi Mei Foundation Medical Ct | Buprenorphinesterderivate, verfahren zu ihrer herstellung, und langwirksame analgetische arzneimittel |
| PL1768650T3 (pl) | 2004-06-04 | 2009-01-30 | Camurus Ab | Ciekłe formulacje depot |
| WO2007061739A2 (en) * | 2005-11-21 | 2007-05-31 | Schering-Plough Ltd. | Pharmaceutical compositions comprising buprenorphine |
| GB0606124D0 (en) | 2006-03-28 | 2006-05-03 | Reckitt Benckiser Healthcare | Buprenorphine derivatives and uses thereof |
| ES2549115T3 (es) * | 2006-09-22 | 2015-10-23 | Zynerba Pharmaceuticals, Inc. | Profármacos de buprenorfina administrables por vía transdérmica y composiciones resistentes al consumo excesivo de los mismos |
| US20090181068A1 (en) * | 2008-01-14 | 2009-07-16 | Dunn Richard L | Low Viscosity Liquid Polymeric Delivery System |
| GB2481018B (en) * | 2010-06-08 | 2015-03-18 | Rb Pharmaceuticals Ltd | Injectable flowable composition comprising buprenorphine |
| GB2513060B (en) | 2010-06-08 | 2015-01-07 | Rb Pharmaceuticals Ltd | Microparticle buprenorphine suspension |
| FR2975912B1 (fr) | 2011-05-30 | 2013-06-14 | Flamel Tech Sa | Composition a liberation controlee de buprenorphine |
| US9393211B2 (en) | 2013-03-15 | 2016-07-19 | Oakwood Laboratories LLC | High drug load buprenorphine microspheres and method of producing same |
| GB201404139D0 (en) * | 2014-03-10 | 2014-04-23 | Rb Pharmaceuticals Ltd | Sustained release buprenorphine solution formulations |
| GB201419091D0 (en) * | 2014-10-27 | 2014-12-10 | Camurus Ab | Formulations |
-
2017
- 2017-09-12 PL PL17850245.6T patent/PL3512518T3/pl unknown
- 2017-09-12 KR KR1020197009185A patent/KR102244500B1/ko active Active
- 2017-09-12 FI FIEP17850245.6T patent/FI3512518T3/fi active
- 2017-09-12 SI SI201731295T patent/SI3512518T1/sl unknown
- 2017-09-12 CA CA3033046A patent/CA3033046C/en active Active
- 2017-09-12 MX MX2019002675A patent/MX374304B/es active IP Right Grant
- 2017-09-12 TW TW106131215A patent/TWI743193B/zh active
- 2017-09-12 US US16/098,864 patent/US10744132B2/en active Active
- 2017-09-12 BR BR112019004923A patent/BR112019004923A2/pt not_active Application Discontinuation
- 2017-09-12 WO PCT/CN2017/101327 patent/WO2018050043A1/en not_active Ceased
- 2017-09-12 JP JP2019535434A patent/JP6929367B2/ja active Active
- 2017-09-12 HU HUE17850245A patent/HUE060906T2/hu unknown
- 2017-09-12 PE PE2019000487A patent/PE20190707A1/es unknown
- 2017-09-12 DK DK17850245.6T patent/DK3512518T3/da active
- 2017-09-12 SG SG11201901294QA patent/SG11201901294QA/en unknown
- 2017-09-12 ES ES17850245T patent/ES2934721T3/es active Active
- 2017-09-12 PT PT178502456T patent/PT3512518T/pt unknown
- 2017-09-12 CN CN201780055635.3A patent/CN109789137B/zh active Active
- 2017-09-12 AU AU2017325910A patent/AU2017325910B2/en active Active
- 2017-09-12 EP EP17850245.6A patent/EP3512518B1/en active Active
- 2017-09-12 SM SM20230006T patent/SMT202300006T1/it unknown
- 2017-09-12 MY MYPI2019000910A patent/MY196269A/en unknown
- 2017-09-12 RU RU2019102895A patent/RU2747306C2/ru active
- 2017-09-12 LT LTEPPCT/CN2017/101327T patent/LT3512518T/lt unknown
- 2017-09-12 RS RS20230034A patent/RS63894B1/sr unknown
- 2017-09-12 HR HRP20230062TT patent/HRP20230062T8/hr unknown
- 2017-09-13 AR ARP170102519A patent/AR110468A1/es not_active Application Discontinuation
-
2019
- 2019-02-12 ZA ZA2019/00890A patent/ZA201900890B/en unknown
- 2019-03-01 PH PH12019500466A patent/PH12019500466A1/en unknown
- 2019-03-12 CL CL2019000624A patent/CL2019000624A1/es unknown
- 2019-04-11 CO CONC2019/0003632A patent/CO2019003632A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019500466A1 (en) | Sustained-release buprenorphine formulations | |
| CY1123597T1 (el) | Σκευασματα ινσουλινης για γρηγορη προσληψη | |
| CO2019007888A2 (es) | Inhibidores selectivos de jak1 | |
| CL2018002803A1 (es) | Antagonistas de c5ar solubles | |
| DOP2018000297A (es) | Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo | |
| MX378315B (es) | Derivados de ácido biliar como agonistas de fxr/tgr5 y métodos para el uso de los mismos | |
| MX2015014656A (es) | Formulaciones de liberacion prolongada de colchicina y metodos de uso de las mismas. | |
| UY33183A (es) | Compuestos inhibidores de virus flaviviridae, composición farmaceutica que los contiene y su uso en la manufactura de un medicamento | |
| WO2015120231A3 (en) | Stable peptide formulations and methods for preparation | |
| BR112016001544A8 (pt) | composições farmacêuticas para a administração intraocular que compreende um agente antibacteriano e um agente anti-inflamatório | |
| MD20160012A2 (ro) | Formulare de inhibitori SYK | |
| PH12019502150A1 (en) | Compounds and methods for the treatment of parasitic diseases | |
| MX2019003103A (es) | Composicion farmaceutica. | |
| WO2014118808A3 (en) | Ticagrelor solid dispersion | |
| CY1120530T1 (el) | Απο του στοματος χορηγησιμη φαρμακευτικη συνθεση | |
| CY1122596T1 (el) | Νεες φαρμακοτεχνικες μορφες (τριμεθοξυφαινυλαμινο)πυριμιδινυλιου | |
| MX390011B (es) | Metodos y composiciones para inhibir los sintomas asociados con la veisalgia. | |
| EP4013418A4 (en) | DERMAL PHARMACEUTICAL FORMULATION OF URACIL | |
| MX376741B (es) | Composición farmaceútica de sulfonamida | |
| BR112015018200A2 (pt) | composição mastigável para administração oral e processo para preparar a mesma | |
| MX2013001279A (es) | Composicion farmaceutica con un inhibidor selectivo de la enzima fosfodiesterasa en forma de gel oral. | |
| WO2016005995A3 (en) | Glycol free stable liquid compositions of bendamustine | |
| WO2015087267A3 (en) | Stable bromfenac ophthalmic solution | |
| TH1901001467A (th) | สูตรผสมบิวพรีนอร์ฟีนที่มีการปลดปล่อยแบบทยอย | |
| MX2020002606A (es) | Composiciones inyectables de acetato de medroxiprogesterona y metodos de uso. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |